CClinicalTrials.gg
Sign In
TerminatedNCT00695487THCUpdated Mar 12, 2014

Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?

An interventional study of THC 9-d-tetra hydro cannabinol in Nausea and Vomiting, sponsored by Insel Gruppe AG, University Hospital Bern. Terminated at 1 site in Switzerland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-12.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment

Why this study was terminated
In the intermediate analysis, no effect could be shown, not even a tendency.
Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The investigators evaluate if intravenously applied THC (Cannabis) reduces postoperative Nausea and vomiting. THC will be given during anesthesia before emergence. We measure how long and how effective it reduces PONV

02

Conditions studied

  • Nausea
  • Vomiting

Keywords

  • Anesthesia
  • THC
  • Postoperative Nausea
03

In context

Nausea

822 studies on the registry are indexed under Nausea; 104 are open to participants now.

This study's enrollment of 320 is above the median of 115 across 703 interventional studies indexed under Nausea.

Browse Nausea studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 724 studies on the registry; 177 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ASA I-III
  • elective open and laparoscopic surgery >1hour

Exclusion criteria

Exclusion Criteria:

  • ambulatory surgery
  • pregnancy, breast feeding
  • >ASA III
  • BMI >35
  • antipsychotic, antiemetic, cytostatic therapy
  • major cardiovascular, renal, hepatic, central nervous system disease
  • current chronic cannabis consumption and hard drug abuse
  • schizophrenia
  • preoperative nausea and vomiting, vestibular disease
  • not speaking german or french
  • refusal to participate
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    1

    Receives 0.125mg/kg THC before emergence

    Drug: THC 9-d-tetra hydro cannabinol

  • Placebo comparator
    2

    Receives NaCl before emergence

    Drug: THC 9-d-tetra hydro cannabinol

Interventions

  • DrugTHC 9-d-tetra hydro cannabinol

    0.125mg/kg iv one time

06

What researchers measure

Primary outcomes

  1. Absence of postoperative Nausea and Vomiting

    Time frame: 0-24h after Operation

Secondary outcomes

  1. Psychological and physiological data after ingestion of THC Analgetics required

    Time frame: 0-24h after operation

07

Study locations

1 site
  • Inselspital, Bern University Hospital
    Bern, 3010, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00695487
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Responsible party
Sponsor
First posted
Jun 12, 2008
Start date
Jul 2008
Primary completion
Dec 2010
Completion
Dec 2011
Last update
Mar 12, 2014

Study contacts

Robert Greif, MD
study director · Department of Anesthesia, Bern University Hospital , Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nausea→

Other studies from this sponsor

Insel Gruppe AG, University Hospital Bern

Start the discussion